CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers

Asish C. Misra, Kathryn E. Luker, Hakan Durmaz, Gary D. Luker, Joerg Lahann*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1′-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies. (Figure Presented).

Original languageEnglish
Pages (from-to)2412-2417
Number of pages6
Issue number8
Publication statusPublished - 10 Aug 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 American Chemical Society.


FundersFunder number
Army Research OfficeW911NF-10-1-0518
U.S. Department of DefenseW81XWH-11-1-0111
National Cancer InstituteR01CA170198


    Dive into the research topics of 'CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers'. Together they form a unique fingerprint.

    Cite this